PepGen delays study for Duchenne drug as it awaits safety data from another trial
PepGen is “temporarily pausing” a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday.
PepGen told
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
